For the Q2 results, all eyes are likely to be on the company’s outlook. The FY 2024 guidance is unlikely to be reached. However, the consensus has already priced this in. The historical premium for Remy is now out of the picture and this might be an enticing entry point for the stock.

25 Oct 2023
Q2-Preview: is it the right time to buy? Capitalizing on the expected weaknesses

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2-Preview: is it the right time to buy? Capitalizing on the expected weaknesses
- Published:
25 Oct 2023 -
Author:
Davide Amorim -
Pages:
3 -
For the Q2 results, all eyes are likely to be on the company’s outlook. The FY 2024 guidance is unlikely to be reached. However, the consensus has already priced this in. The historical premium for Remy is now out of the picture and this might be an enticing entry point for the stock.